Close Menu

IPO

The Canadian firm, which already floats on the Toronto Stock Exchange, is gearing up for the launch of its LungExpress Dx product in the US.

RBM, which held around $3 million in cash and cash equivalents as of the end of September, is developing a psychiatric diagnostics panel.

The proceeds will support commercialization of the company's gene expression-based assay for early-stage non-small-cell lung cancer.

Speaking after the firm's presentation Monday at the UBS Global Life Sciences Conference, Fluidigm CFO Vikram Jog told GenomeWeb Daily News that the company still intends to go public, but the timing remains uncertain.

The funding will support PacBio's effort to launch its SMRT sequencing system in the second half of 2010, and will also serve as a financial "buffer" as the company looks to pursue an initial public offering or other large-scale financing effort some time next year.

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.